This study aims to discover and validate new biomarkers for predicting CSA-AKI before cardiovascular surgery.
Nested case-control studies embedded in prospective cohorts. Adult patients scheduled for cardiovascular surgery were continuously included. Blood/urine/stool samples and clinical data before and after contrast agent exposure and before and after cardiovascular surgery were collected, and the occurrence, progression and outcome of CSA-AKI events were dynamically monitored. Based on the exposure to contrast agents and the occurrence of CSA-AKI, two case-controls were constructed in the prospective cohort. In the construction of two case-controls, biomarkers were identified and validated by using multi-omics analysis techniques and machine learning techniques, etc.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1\. Age no less than 18 years old;
* 2\. Scheduled cardiovascular surgery is proposed;
* 3\. Pre-angiography and preoperative serum creatinine \<354 μ mol/L;
* 4\. Informed consent.
Exclusion Criteria:
* 1\. Women who have a pregnancy plan within one year, are pregnant, or are breastfeeding;
* 2\. Patients who have severe side effects such as allergies to iodine contrast agents;
* 3\. Patients with hyperthyroidism;
* 4\. Those who had AKI before the contrast agent or within 2 weeks before the operation, or whose AKI has not been relieved after the operation;
* 5\. Patients undergoing kidney transplantation, peritoneal dialysis, or hemodialysis treatment;
* 6\. Patients with malignant tumors or those with an expected lifespan of less than 12 months;
* 7\. Angiography or preoperative acute heart failure;
* 8\. Patients who have a history of massive hemorrhage in the past 30 days or have contraindications to anticoagulant therapy.
Primary outcome measure(s)
The occurrence of CSA-AKI — The assessment will be conducted from the end of the surgery until the 7th day after the operation. CSA-AKI is defined as: serum creatinine (SCr) within 48 hours after cardiovascular surgery increases by ≥26.5 µmol/L compared with the baseline, or SCr increases by ≥ 50% times the baseline value within 7 days after surgery, or urine output is less than 0.5 mL/kg/h and persists for more than 6 hours.
Trial sites (1)
Facility
City
Region
Status
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases
Beijing
Beijing Municipality
Recruiting
More China National Center for Cardiovascular Diseases trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.